Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/enojCfbwocfEsjuBAgdX

March 15, 2013
Sign upForwardArchiveAdvertiseRead more at SmartBrief.com
News for nuclear medicine and molecular imaging professionals
 
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at snmmi@smartbrief.com.

  Top Story 
  • CMS considers easing PET reimbursement for most cancers
    CMS has released a decision memo with a proposal to lift the requirement that FDG-PET scans in cases involving solid tumors be reported to the National Oncologic PET Registry. Providers will no longer have to send the data to the registry as a reimbursement condition if the proposal is approved. CMS said it will reimburse one FDG-PET or PET/CT scan used to assess initial cancer therapy for most indications except prostate cancer. Coverage for subsequent scans will be determined by local Medicare contractors, CMS said. AuntMinnie.com (free registration) (3/14) LinkedInFacebookTwitterEmail this Story
  Clinical News & Research 
  • Breast cancer treatment tied to heart disease risk
    Women who undergo radiation treatment for breast cancer face increased risk of developing heart trouble later in life, according to a study published in the New England Journal of Medicine. The study found radiation can promote hardened and clogged arteries, which are risk factors for heart attack. Researchers emphasized that the increased risk is small, and the cancer treatment saves lives. Designing EMRs to act like personal dosimeters for radiation exposure may help limit risks, said Dr. David Slosky, a Vanderbilt University cardiologist. The Plain Dealer (Cleveland)/The Associated Press (3/14) LinkedInFacebookTwitterEmail this Story
 
  Industry Report 
  • Cell>Point enters deal for commercialization of imaging agents
    Cell>Point said it has secured a licensing deal with South Korean firm Hanmi Pharmaceutical. The agreement involves the development and commercialization of Cell>Point's cancer and cardiology imaging agent, to be developed through its ethylenedicysteine-glucosamine technology. The partnership will initially produce technetium-99m-labeled EC-G for SPECT and SPECT/CT uses. The collaboration will cover gallium-68-labeled EC-G for PET/CT imaging later on. Business Wire/News release (3/11) LinkedInFacebookTwitterEmail this Story
  News from the Field 
  • BioClinica to merge with CoreLab Partners
    BioClinica, a company that oversees medical imaging and data collection for clinical development of drugs and devices, is set to merge with CoreLab Partners. Private equity firm JLL Partners is in the process of acquiring BioClinica and CoreLab to merge the two entities. The Philadelphia Inquirer (3/15) LinkedInFacebookTwitterEmail this Story
  Health Policy 
  Advancing Health Care 
  • EMR tool tracks cognitive function in older adults
    Specialists from the Indiana University Center for Aging Research and the Regenstrief Institute have unveiled the Electronic Medical Record Aging Brain Care (EMR-ABC) software to help care coordinators monitor the cognitive function of older adults. "The software we have developed will help care coordinators measure the many needs of patients and their loved ones and monitor the effectiveness of individualized care plans," said Regenstrief Institute researcher Dr. Malaz Boustani. Healthcare Informatics online (3/14) LinkedInFacebookTwitterEmail this Story
  • Ethicists consider oversight of patient-led research
    As more patients become citizen-scientists and conduct research on themselves, with peer-reviewed journals increasingly publishing the results, ethicists are considering how to tailor ethical oversight to reduce bias and increase safety. Ethical oversight needs to be flexible enough to accommodate the distinctive character and various forms of patient-led research, Institute of Biomedical Ethics research fellow Effy Vayena writes. Vayena and colleagues discuss in the journal PLoS Medicine possible models for oversight. The Scientist online (3/13) LinkedInFacebookTwitterEmail this Story
  From SNMMI 
  • Maintain your certification with SNMMI's self-assessment modules (SAMs)
    Earn the self-assessment credit hours needed to maintain your certification. New modules are now available, including Bringing Physiology into PET of the Liver, Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias, Modern Nuclear Imaging for Paragangliomas: Beyond SPECT, Oncologic PET/MRI, Part 1: Tumors of the Brain, Head and Neck, Chest, Abdomen, and Pelvis, and Effectiveness and Safety of FDG-PET in the Evaluation of Dementia. Get started today. LinkedInFacebookTwitterEmail this Story
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

  SmartQuote 
Adventure is not outside man; it is within."
--George Eliot,
British writer


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
   
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Advertise
Account Director:   Meryl Harold   (202) 407-7828
 
Read more at SmartBrief.com
 
 
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.®  Legal Information